{"prompt": "['IRB Approved', 'Document Release Date: 02/26/2020', 'CC Protocol Number: 9582', 'PI: Michael T. Schweizer, MD', 'Apalutamide in Active Surveillance patients', 'Protocol Version: 6.0; September 06, 2019', 'Janssen Scientific Affairs, LLC or their designees. These biologic samples will be retained for up', 'to 5 years following the last patient completing the study, and any remaining samples will be', 'destroyed after that time. Likewise, data generated as part of this study will be stored on secure', 'servers at University of Washington and/or Janssen Scientific Affairs, LLC and access will be', 'limited to the Sponsor-Investigator, Co-Investigators, Janssen Scientific Affairs, LLC or their', 'designees. The identity of enrolled subjects will remain confidential, and only the treating', 'physician, research team, and/or Sponsor-Investigator will have access to this information.', 'Patient identifiers will not be made available to the Janssen Scientific Affairs, LLC.', 'Study Population:', \"Men with very low-risk to low-intermediate risk prostate cancer (see 'risk' definitions under\", 'inclusion criteria) enrolled (or planning to enroll) on active surveillance.', 'Number of Patients: Up to 33 patients at University of Washington Medical Center.', 'Inclusion Criteria:', '1. Have signed an informed consent document.', '2. Be willing/able to adhere to the prohibitions and restrictions specified in this protocol', '3. Written authorization for use and release of health and research study information has been', 'obtained (i.e., HIPAA authorization)', '4. Male aged 18 to 75 years or life expectancy >10 years (as determined by the treating', 'physician)', '5.', 'Eastern cooperative group (ECOG) performance status 1', '6. Histologically confirmed adenocarcinoma of the prostate as documented by a minimum 12', 'core prostate biopsy completed within 1-year of enrollment (Note: most recent prostate', 'biopsy must have demonstrated prostatic adenocarcinoma)', '7. Favorable risk prostate cancer as defined by:', 'Very low-risk', 'a. Clinical stage T1c disease', 'b. PSA density (PSAD) <0.15 ng/mL', 'C. Gleason score 6', 'd. 2 core biopsies with <50% involvement of any biopsy core with cancer, or', 'unilateral disease <2 core biopsies with any percentage involvement', 'or', 'Low risk', 'a.', 'Clinical stage T2a', 'b. PSA < 15 ng/mL', 'C. Gleason score 6', 'or', 'Low-intermediate risk', 'a. Clinical stage T1c', 'b. PSA <15 ng/ml', 'C. Gleason 3+4 present in <50% of one core/site as detected by systematic biopsy', 'or MRI/TRUS fusion guided biopsy', 'd. Gleason 6 disease in all other cores', '4', 'Printed on 1/29/2021']['IRB Approved', 'Document Release Date: 02/26/2020', 'CC Protocol Number: 9582', 'PI: Michael T. Schweizer, MD', 'Apalutamide in Active Surveillance patients', 'Protocol Version: 6.0; September 06, 2019', '8. Willing and qualified for active surveillance at University of Washington', '9. Serum testosterone >150 ng/dL', '10. Able to swallow the study drugs whole as a tablet', '11. Clinical laboratory values at screening:', 'a. Hemoglobin >9.0 g/dL, independent of transfusion and/or growth factors within', '3 months prior to randomization', 'b. Platelet count >100,000 x 109/L independent of transfusion and/or growth', 'factors within 3 months prior to registration', 'C. Serum albumin >3.0 g/dL', 'd. GFR >45 mL/min', 'e. Serum potassium >3.5 mmol/L', 'f.', \"Serum total bilirubin <1.5 x ULN (Note: In subjects with Gilbert's syndrome, if\", 'total bilirubin is >1.5 x ULN, measure direct and indirect bilirubin and if direct', 'bilirubin is <1.5 x ULN, subject may be eligible)', 'g.', 'Aspartate aminotransferase (AST) or alanine aminotransferase (ALT)', '<2.5 x ULN', '12. Medications known to lower the seizure threshold (see list under prohibited meds) must be', 'discontinued or substituted at least 4 weeks prior to study entry.', '13. Agrees to use a condom (even men with vasectomies) and another effective method of birth', 'control if he is having sex with a woman of childbearing potential or agrees to use a condom', 'if he is having sex with a woman who is pregnant while on study drug and for 3 months', 'following the last dose of study drug. Must also agree not to donate sperm during the study', 'and for 3 months after receiving the last dose of study drug.', 'Exclusion Criteria:', '1. Prior local therapy to treat prostate cancer (e.g., radical prostatectomy, radiation therapy,', 'brachytherapy)', '2. Prior use of ARN-509 (apalutamide)', '3. Have known allergies, hypersensitivity, or intolerance to ARN-509 (apalutamide) or its', 'excipients', '4. Prior or ongoing systemic therapy for prostate cancer including, but not limited to:', 'a. Hormonal therapy (e.g., leuprolide, goserelin, triptorelin)', 'b. CYP-17 inhibitors (e.g., abiraterone, ketoconazole)', 'C. Antiandrogens (e.g., bicalutamide, nilutamide)', 'd. Second generation antiandrogens (e.g., enzalutamide)', 'e. Immunotherapy (e.g., sipuleucel-T, ipilimumab)', 'f. Chemotherapy (e.g., docetaxel, cabazitaxel)', '5. Have any condition that, in the opinion of the investigator, would compromise the well-being', 'of the subject or the study or prevent the subject from meeting or performing study', 'requirements', '6. History of any of the following:', 'a. Seizure or known condition that may pre-dispose to seizure (including but not', 'limited to prior stroke, transient ischemic attack, loss of consciousness within', '1 year prior to registration, brain arteriovenous malformation; or intracranial', '5', 'Printed on 1/29/2021']\n\n###\n\n", "completion": "END"}